FilingReader Intelligence
Marksans Pharma reports strong Q1 2025 results
August 12, 2025 at 07:49 AM UTC•By FilingReader AI
Marksans Pharma Ltd. reported standalone revenue of INR 3,197.34 million for Q1 2025, with profit after tax reaching INR 480.56 million. Basic earnings per share stood at INR 1.06.
On a consolidated basis, revenue hit INR 6,199.89 million with profit after tax of INR 582.02 million. Consolidated earnings per share were INR 1.29.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
BSE:MARKSANS•Bombay Stock Exchange
News Alerts
Get instant email alerts when Marksans Pharma publishes news
Free account required • Unsubscribe anytime